BIRC2 and cancer: Previous studies reported that IAPs such as cIAP1, cIAP2, and XIAP promote resistance to anoikis in several cancers, through caspase inhibition (Toruner et al., 2006; Liu et al., 2006; Berezovskaya et al., 2005).